肥胖与重度肥胖HIV感染者的抗逆转录病毒药物暴露与应答:结合建模与瑞士HIV队列数据的研究
研究采用生理药代动力学(PBPK)建模结合瑞士HIV队列研究(SHCS)治疗药物监测数据,在BMI 18.5–60 kg/m²的虚拟成人中预测不同肥胖等级的抗逆转录病毒药物(ARV)药代动力学。模型预测肥胖者(BMI≥30 kg/m²)较非肥胖者(BMI 18.5–25 kg/m²)ARV暴露平均降低约20%、谷浓度降低约6%,与观察数据一致;依曲韦林和利匹韦林受影响最大。SHCS中肥胖者病毒载量未抑制率不高于非肥胖者,作者认为标准剂量适用于肥胖HIV感染者。
要点
- PBPK模型预测肥胖者较非肥胖者ARV暴露平均降低约20%、谷浓度降低约6%,与SHCS观察数据一致。
- 依曲韦林和利匹韦林受影响最大,BMI>40 kg/m²者谷浓度低于临床目标阈值。
- SHCS中肥胖HIV感染者病毒载量未抑制率不高于非肥胖者,作者认为标准剂量适用。
核心结论
- 肥胖个体中ARV浓度适度降低,对病毒学应答无负面影响;数据支持标准剂量ARV适用于肥胖HIV感染者,包括使用部分一线ARV后体重明显增加者。
研究设计与样本
- 采用生理药代动力学(PBPK)建模进行虚拟试验,结合瑞士HIV队列研究(SHCS)治疗药物监测数据验证模型预测性能。
- 每个虚拟试验纳入BMI 18.5–60 kg/m²的虚拟成人队列,模型应用于预测不同肥胖等级的ARV药代动力学。
- 在肥胖与非肥胖个体中分析ARV血浆浓度与病毒学应答的关联。
主要发现
- PBPK模型预测肥胖者(BMI≥30 kg/m²)较非肥胖者(BMI 18.5–25 kg/m²)ARV暴露平均降低约20%、谷浓度降低约6%,与观察临床数据一致。
- 依曲韦林和利匹韦林受影响最大,尤其BMI>40 kg/m²者谷浓度低于临床目标阈值。
- SHCS中肥胖HIV感染者病毒载量未抑制率不高于非肥胖HIV感染者。
临床怎么用
- 作者认为标准剂量的ARV适用于肥胖HIV感染者,包括使用部分一线ARV后体重明显增加者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is increasingly prevalent among people with HIV (PWH) and can possibly result in suboptimal antiretroviral drug (ARV) exposure and response. However, this has not been thoroughly evaluated given that obese PWH are underrepresented in clinical trials. We performed virtual trials using physiologically based pharmacokinetic (PBPK) modelling combined with observed clinical data to provide ARV dosing guidance in obese individuals. METHODS: Each trial included a cohort of virtual adults with a body mass index (BMI) between 18.5 and 60 kg/m2. Therapeutic drug-monitoring data from the Swiss HIV Cohort Study (SHCS) were used to verify the predictive performance of the model. Subsequently, the model was applied to predict the pharmacokinetics of ARVs for different obesity classes. The association between ARV plasma concentrations and virological response was investigated in obese and nonobese individuals. RESULTS: The PBPK model predicted an average reduction in ARV exposure of ∼20% and trough concentrations of ∼6% in obese (BMI ≥30 kg/m2) compared with nonobese (BMI: 18.5-25 kg/m2) individuals, consistent with observed clinical data. Etravirine and rilpivirine were the most impacted, especially in individuals with BMI >40 kg/m2 whose trough concentrations were below the clinical target threshold. Obese PWH in the SHCS did not have a higher rate of unsuppressed viral load than nonobese PWH. CONCLUSIONS: The concentrations of ARVs are modestly reduced in obese individuals, with no negative impact on the virological response. Our data provide reassurance that standard doses of ARVs are suitable in obese PWH, including those who gained substantial weight with some of the first-line ARVs.
引用
- Berton M, Bettonte S, Stader F, et al. Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data. Clin Infect Dis. 2024. PMID: 37602428. doi:10.1093/cid/ciad495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。